REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Adult > Chapters > 1. Gastro-Intestinal System >

BNSSG Adult Joint Formulary

1.8 Obesity

Last edited: 23-04-2025

First line drugs Second line drugs Specialist drugs Secondary care drugs

 

Lipase Inhibitors

Orlistat (TLS Green) - primary care initiation only

 

GLP-1 (Glucagon- Like Peptide 1) Receptor

The FSRH is advising that individuals use contraception whilst using GLP-1 agonists, with additional advice for those using tirzepatide. The FSRH has also produced a patient information leaflet for clinicians to share with patients. 

Liraglutide (Saxenda®) (TLS Red)

  • NICE TA664 Liraglutide for managing overweight and obesity

Semaglutide (Wegovy®) (TLS Red)

  • NICE TA875 Semaglutide for managing overweight and obesity

Tirzepatide (Mounjaro®) (TLS Red)

  • NICE TA1026 Tirzepatide for managing overweight and obesity
  • Notes NHS England’s proposals for a phased launch of tirzepatide (Mounjaro) for weight management: 
  • From 1st April 2025, Tier 3 Specialist Weight Management Services will be able to assess patients for eligibility for tirzepatide in line with NICE TA1026 criteria.
  • Primary care based services are being developed to offer tirzepatide to eligible patients, in line with NHSE agreed priority cohorts, by the end of June 2025. GP practices should not currently prescribe tirzepatide for weightloss.
  • For information on the implementation of tirzepatide for weight loss see BNSSG ICS update April 2025. Also see Tirzepatide FAQs for BNSSG Healthcare professionals and Tirzepatide FAQs for patients.

For use of GLP-1s in Type 2 diabetes see formulary Chapter 6.3

Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.